Norroy Bioscience gets China NMPA approval to initiate pivotal phase III trial of 177Lu-NYM032, a PSMA-targeted radioligand therapy for mCRPC

Norroy Bioscience (Norroy), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical Products

To access the full article, please log in or subscribe.